{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-021408","form_type":"8-K","ticker":"BJDX","cik":"0001704287","company_name":"Bluejay Diagnostics, Inc.","filed_at":"2023-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.205440+00:00","generated_at":"2026-06-17T23:00:57.676467+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bluejay Diagnostics reports 2022 net loss $9.3M; FDA submission delayed to H1 2024","bullets":["Net loss $9.3M ($0.46 per share) vs $3.5M ($0.41 per share) in 2021.","Cash and cash equivalents $10.1M, down from $19.0M year-over-year.","R&D expense increased 262% to support clinical trials for planned FDA submission.","FDA feedback requires expanded clinical study; de novo submission timeline pushed to H1 2024.","Company to require additional funding to reach commercialization due to delay."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-021408","json":"https://secwatch.observer/filing/0001213900-23-021408.json","markdown":"https://secwatch.observer/filing/0001213900-23-021408.md","text":"https://secwatch.observer/filing/0001213900-23-021408.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704287/000121390023021408/0001213900-23-021408-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704287/000121390023021408/ea175516-8k_bluejay.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T23:00:57.676467+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf50a4b831184bbbbb4a9f1242ed2ec63cb0fd6c","claim":"Bluejay Diagnostics, Inc. reported the year ended December 31, 2022 results: net income $9.3 million, or $0.46 per share, EPS $0.46 per share.","evidence_excerpt":"Bluejay Diagnostics Reports 2022 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390023021408/0001213900-23-021408-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"$9.3 million, or $0.46 per share"},{"label":"EPS","value":"$0.46 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}